Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR)

被引：15
|
作者：
Lee, J.
Hirsh, V.
Park, K.
Qin, S.
Blajman, C. R.
Perng, R.
Emerson, L.
Langmuir, P. B.
Manegold, C.
机构：
[1] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[2] McGill Univ Hlth Ctr, Montreal, PQ, Canada
[3] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] 81 Hosp Chinese Peoples Liberat Army, Nanjing, Jiangsu, Peoples R China
[5] Isis Ctr Especializado, Rosario, Santa Fe, Argentina
[6] Vet Gen Hosp, Taipei, Taiwan
[7] AstraZeneca, Loughborough, Leics, England
[8] AstraZeneca, Wilmington, DE USA
[9] Univ Med Ctr, Mannheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7525
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC).
    Johnson, EA
    Marks, RS
    Mandrekar, S
    Hillman, S
    Mailliard, J
    Dentchev, T
    Reuter, N
    Jett, J
    Perez, EA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 634S - 634S
  • [22] A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
    Postel-Vinay, S.
    Planchard, D.
    Granados, A. L. Ortega
    Gazzah, A.
    Gonzalez, M. A. Sala
    Majem, M.
    Camps, C. J.
    Abou-Lauvergne, A.
    Pignon, J-P.
    Cadranel, J.
    Bennouna, J.
    Barlesi, F.
    Campelo, M. R. Garcia
    Viteri, S.
    Besse, B.
    Sarto, J. Coves
    Sureda, B. Massuti
    Soria, J-C.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial
    DeGregorio, Michael
    Soe, Lin
    Wolf, Michael
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 571 - 573
  • [24] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).
    Tran, HT
    Zinner, R
    Blumenschein, GR
    Oh, YW
    Papadimitrakopoulou, VA
    Kim, ES
    Lu, C
    Malik, M
    Lum, B
    Herbst, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [25] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
    Raez, L. E.
    Baca, Y.
    Nagasaka, M.
    Nieva, J.
    Mandani, H.
    Wanderwalde, A.
    Borghaei, H.
    Naban, C.
    Langer, C.
    Socinsky, M. A.
    Lopes, G.
    Khan, H.
    Wozniak, A.
    Carracedo, C.
    Liu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
  • [26] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
    de Boer, Richard H.
    Arrieta, Oscar
    Yang, Chih-Hsin
    Gottfried, Maya
    Chan, Valorie
    Raats, Johann
    de Marinis, Filippo
    Abratt, Raymond P.
    Wolf, Juergen
    Blackhall, Fiona H.
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1067 - 1074
  • [27] A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
    Si, Xiaoyan
    Wang, Jinwan
    Cheng, Ying
    Shi, Jianhua
    Cui, Liying
    Zhang, Helong
    Huang, Yunchao
    Liu, Wei
    Chen, Lei
    Zhu, Jiang
    Zhang, Shucai
    Li, Wei
    Sun, Yan
    Wang, Hanping
    Zhang, Xiaotong
    Wang, Mengzhao
    Yang, Lin
    Zhang, Li
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [28] A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC)
    Lee Siow-Ming
    Woll, Penella J.
    Rudd, Robin M.
    Gower, Nicole H.
    Ottensmeier, Christian H.
    Ali, Kulsam
    Spiro, Stephen G.
    Hackshaw, Allan
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S359 - S359
  • [29] Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
    Hanna, Nasser H.
    Kaiser, Rolf
    Sullivan, Richard N.
    Aren, Osvaldo Rudy
    Ahn, Myung-Ju
    Tiangco, Beatrice
    Voccia, Isabelle
    von Pawel, Joachim
    Kovcin, Vladimir
    Agulnik, Jason
    Gaschler-Markefski, Birgit
    Barrueco, Jose
    Sikken, Patricia
    Schloss, Charles
    Kim, Joo-Hang
    LUNG CANCER, 2016, 102 : 65 - 73
  • [30] Functional Lung Avoidance Radiation Therapy for Stage III Non-Small Cell Lung Cancer: A Double-Blind Randomized Phase 2 Trial
    Yaremko, B.
    Palma, D. A.
    Parraga, G.
    Capaldi, D.
    Sheikh, K.
    Rodrigues, G.
    Dar, A. R.
    Louie, A. V.
    Yu, E.
    Gaede, S.
    Hoover, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S89 - S89
12345